Sizavaleucel

Summary

Sizavaleucel (CHEMBL5095445) is a phase-3 clinical-stage cell; indicated across 1 condition including graft versus host disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095445
Name	Sizavaleucel
Type	Cell
Max phase	3

Also known as: MDR-101, Sizavaleucel, SIZAVALEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
graft versus host disease	3	MONDO:0013730	EFO:0004599

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03363945	PHASE3	COMPLETED	Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).